Searched for
DRL NEWS
Reddy Pharma loses 'name' in Delhi HC rulingThe Delhi High Court has ruled against Reddy Pharmaceuticals. The court upheld a decision to remove 'Reddy' from the company's name. Reddy ...- 'Factually incorrect': Dr Reddy's denies 25% workforce cost reduction claimDr. Reddy's Laboratories has refuted a media report alleging a significant workforce cost reduction initiative. The report claimed the comp...
- Dr Reddy’s slashing jobs to cut costs by 25%, asks several Rs 1 crore+ earners to resign; co denies reportDr. Reddy's Laboratories is implementing cost-cutting measures, aiming to reduce manpower expenses by 25%. High-salaried employees, includi...
- Dr Reddy's shares rally 4% as Nuvama upgrades rating to buyDr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate the impact of Re...
- Dr Reddy's Q3 Results: Net profit rises 11% YoY to Rs 1,379 crore, meets estimatesDRL Q3 Results: The profit was slightly above the ET Now poll estimate of Rs 1,337 crore. Revenue from operations increased 7% year-on-year...
- Dr Reddy's Laboratories jumps into the fray for Biogen's biosimilarsDr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- Dr Reddy's tumbles 7% post Q4 results! Here's what brokerages recommendDr Reddy's Laboratories reported an 890% YoY surge in March quarter profit at Rs 960.1 crore but shares tumbled nearly 7% to Rs 4,545 in Th...
- Buy Dr. Reddy's Laboratories, target price Rs 5134: ICICI SecuritiesDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 74243.28 Crore) operating i...
- Dr Reddy’s Q2 results: Consolidated PAT rises 30% YoY, beats estimateThe drugmaker reported an 18 per cent on-year rise in consolidated revenues to Rs. 5,763 crore for the reported quarter, which also beat St...
- Neutral on Dr. Reddy's Laboratories, target price Rs 5200: Motilal OswalDr. Reddy's Laboratories Ltd., incorporated in the year 1984, is a Large Cap company (having a market cap of Rs 80574.04 Crore) operating i...
- Dr Reddy's lines up Rs 1,000 crore capex for current fiscal yearThe Hyderabad based firm invested about Rs 1,000 crore in the 2020-21 fiscal year.
- Can USFDA all-clear for Duvvada earn Dr Reddy’s stock a rerating?The Duvvada news has lifted a big overhang from the stock, said Edelweiss Securities.
- DRL stock slips 5% after US court orderThe scrip was 5.30 per cent down at Rs 2,565.60 at around 02.12 pm.
- Dr Reddy's trades steady, shrugs off legal challengeDRL’s generic version was to be marketed as Ticaflo, according to those in the know.
- USFDA becoming dreaded word in Dalal Street; pharma companies need to keep Street in the loopThe stock of drug major Dr Reddy’s Labs (DRL) crashed 22% in the last three days, swiftly eroding the gains made over the last five months.
- Dr Reddy's Laboratories may file new drug applications with FDA within yearChief Operating Officer and Member of the Management Council, DRL, Abhijit Mukherjee said one drug is currently in the late phase-III .
- Glaxo’s plan to acquire 5% stake in Dr Reddy’s may fizzle outUK-BASED GlaxoSmithKline’s (GSK) plan to buy about 5% stake in Dr Reddy’s Laboratories (DRL) for $150-160 million is stuck and unlikely to ...
- Dr Reddy's cancels warrants issueDr Reddy’s (DRL) scrapped the issue of 8.41 million convertible warrants to the promoters nearly three weeks after receiving the shareholde...
- DRL stops work on new diabetes drugIndia’s largest drug maker, Dr Reddy’s Laboratories, has stopped further development of a new drug aimed at treating diabetes and obesity.
Load More
